Stockreport

Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219

KITOV PHARAMCEUTICALS HOLDINGS LTD AMERICAN DEPOS  (KTOV) 
US:NASDAQ Investor Relations: kitovpharma.com
PDF Patent covers NT219’s combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®) TEL AVIV, Israel, Oct. 27, 2020 (GLOBE [Read more]